Features of gemcitabine-related severe pulmonary toxicity: Patients with pancreatic or biliary tract cancer

Pancreas

Volumn 38, Issue 7, 2009, Pages 838-840

  Tamiya, Akihiro ^a   Endo, Masahiro ^a   Shukuya, Takehito ^a   Igawa, Satoshi ^a   Tsuya, Asuka ^a   Nakamura, Yukiko ^a   Murakami, Haruyasu ^a   Takahashi, Toshiaki ^a   Boku, Narikazu ^a   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; GEMCITABINE; STEROID;

ADULT; ADVERSE OUTCOME; AGED; BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DYSPNEA; FATIGUE; FEMALE; FEVER; HUMAN; HYPOXIA; LETTER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; OXYGEN SATURATION; PANCREAS CANCER; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BILIARY TRACT NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG; LUNG DISEASES; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PNEUMONIA;

EID: 70349902552     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181ad97cf     Document Type: Letter

References (10)

1. Heinemann V, Hertel LW, Grindey GB, et al. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1988;48:4024-4031. (Pubitemid 18174715)
2. Carmichael J, Fink U, Rusesell RCG, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 1996;73:101-105. (Pubitemid 26026268)
3. Okusaka T, Ishii H, Funakoshi A, et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol. 2006;57: 647-653. (Pubitemid 43237850)
4. Pavlakis N, Bell DR, Millward MJ, et al. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997;82: 1800-1801.
5. Attar EC, Ervin T, Janicek M, et al. Side effects of chemotherapy. Case 3. Acute interstitial pneumonitis related to gemcitabine. J Clin Oncol. 2000;18:697-698.
6. Ho Kim D, Shiozawa S, Tsuchiya A, et al. A case of drug-induced interstitial pneumonitis after adjuvant chemotherapy with gemcitabine for pancreatic cancer. Gan To Kagaku Ryoho. 2008;35:133-136.
7. Green MR. Gemcitabine safety overview. Semin Oncol. 1996;23:32-35.
8. Aapro MS, Martin C, Hatty S. Gemcitabine - a safety review. Anticancer Drugs. 1998;9:191-201.
9. Belknap SM, Kuzel TM, Yarnold PR, et al. Clinical features and correlates of gemcitabine-associated lung injury: finding from the RADAR project. Cancer. 2006;106: 2051-2057.
10. LeVitt ML, Kassem B, Gooding WE, et al. Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms. Lung Cancer. 2004;43:335-344. (Pubitemid 38224155)